NewAmsterdam Pharma says EMA panel backs EU approval for Ubeslo, Evlarco cholesterol drugs

• NewAmsterdam Pharma secured a positive CHMP opinion recommending EU marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib-ezetimibe) in primary hypercholesterolemia.
• European Commission decision expected in 2H26, setting up potential European launch with Menarini holding exclusive regional commercialization rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240800PRIMZONEFULLFEED9767421) on July 24, 2026, and is solely responsible for the information contained therein.